JP2019524670A5 - - Google Patents

Download PDF

Info

Publication number
JP2019524670A5
JP2019524670A5 JP2018567638A JP2018567638A JP2019524670A5 JP 2019524670 A5 JP2019524670 A5 JP 2019524670A5 JP 2018567638 A JP2018567638 A JP 2018567638A JP 2018567638 A JP2018567638 A JP 2018567638A JP 2019524670 A5 JP2019524670 A5 JP 2019524670A5
Authority
JP
Japan
Prior art keywords
acid
nanoparticles
item
prodrug
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018567638A
Other languages
English (en)
Japanese (ja)
Other versions
JP7160466B2 (ja
JP2019524670A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/038693 external-priority patent/WO2017223280A2/en
Publication of JP2019524670A publication Critical patent/JP2019524670A/ja
Publication of JP2019524670A5 publication Critical patent/JP2019524670A5/ja
Application granted granted Critical
Publication of JP7160466B2 publication Critical patent/JP7160466B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018567638A 2016-06-23 2017-06-22 治療薬の送達のための組成物及び方法 Active JP7160466B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662353736P 2016-06-23 2016-06-23
US62/353,736 2016-06-23
PCT/US2017/038693 WO2017223280A2 (en) 2016-06-23 2017-06-22 Compositions and methods for the delivery of therapeutics

Publications (3)

Publication Number Publication Date
JP2019524670A JP2019524670A (ja) 2019-09-05
JP2019524670A5 true JP2019524670A5 (enExample) 2020-05-07
JP7160466B2 JP7160466B2 (ja) 2022-10-25

Family

ID=60784694

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018567638A Active JP7160466B2 (ja) 2016-06-23 2017-06-22 治療薬の送達のための組成物及び方法

Country Status (6)

Country Link
US (1) US11117904B2 (enExample)
EP (3) EP3474857B1 (enExample)
JP (1) JP7160466B2 (enExample)
DK (1) DK4299133T3 (enExample)
ES (1) ES3035041T3 (enExample)
WO (1) WO2017223280A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737359A4 (en) 2018-01-12 2021-11-03 Board of Regents of the University of Nebraska ANTIVIRAL PRODRUGS AND THEIR FORMULATIONS
WO2019171285A1 (en) * 2018-03-07 2019-09-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
US11458136B2 (en) 2018-04-09 2022-10-04 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
EP4751717A3 (en) * 2018-10-22 2026-08-05 Board of Regents of the University of Nebraska Antiviral prodrugs and nanoformulations thereof
CN118873676A (zh) 2018-11-29 2024-11-01 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
WO2020146788A1 (en) * 2019-01-11 2020-07-16 University Of Washington Combination pharmaceutical compositions and methods thereof
PH12021500034A1 (en) 2019-03-06 2022-06-06 Glaxosmithkline Ip No 2 Ltd Compounds useful in hiv therapy
KR20240151256A (ko) 2019-03-22 2024-10-17 길리애드 사이언시즈, 인코포레이티드 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도
IL293566A (en) * 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
EP4110783A1 (en) 2020-02-24 2023-01-04 Gilead Sciences, Inc. Tetracyclic compounds for treating hiv infection
CN116390924B (zh) 2020-09-30 2025-11-07 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其用途
CR20260070A (es) 2021-01-19 2026-04-24 Gilead Sciences Inc COMPUESTOS DE PIRIDOTRIAZINA SUSTITUIDOS Y USOS DE ESTOS (Divisional 2023-0315)
WO2023183472A1 (en) * 2022-03-23 2023-09-28 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and use thereof
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
CN120936599A (zh) * 2023-01-18 2025-11-11 歌礼生物科技(杭州)有限公司 整合酶抑制剂及其应用
WO2024227037A1 (en) * 2023-04-26 2024-10-31 University Of Washington Long-acting colloidal pharmaceutical compositions of integrase strand transfer inhibitors and related methods
WO2025011661A1 (zh) * 2023-07-12 2025-01-16 歌礼生物科技(杭州)有限公司 整合酶抑制类的制剂及其制备方法
TW202543636A (zh) 2023-12-12 2025-11-16 美商 Viiv 醫療保健公司 結晶形式
WO2025128498A1 (en) 2023-12-12 2025-06-19 Viiv Healthcare Company Pharmaceutical compositions
WO2026012272A1 (en) * 2024-07-12 2026-01-15 Ascletis Bioscience Co., Ltd. Integrase inhibitor and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3187225T3 (da) 2005-04-28 2022-02-28 Viiv Healthcare Co Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet
EP2660239B1 (en) * 2008-07-25 2016-11-23 VIIV Healthcare Company Chemical compounds as synthetic intermediates
WO2010011812A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011815A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
SMT202100268T1 (it) * 2010-08-05 2021-07-12 Shionogi & Co Metodo per produrre composti aventi attività di inibizione di integrasi di hiv.
TWI577377B (zh) 2010-09-16 2017-04-11 Viiv醫療保健公司 醫藥組合物
JP2013542945A (ja) 2010-11-02 2013-11-28 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ 治療を送達するための組成物および方法
EA030003B1 (ru) * 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
HK1214817A1 (en) 2012-12-27 2016-08-05 Japan Tobacco Inc. Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as hiv integrase inhibitor
WO2015039348A1 (en) * 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
WO2015127437A1 (en) * 2014-02-24 2015-08-27 The Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics

Similar Documents

Publication Publication Date Title
JP2022505928A5 (enExample)
JP2015510930A5 (enExample)
JP2012526094A5 (enExample)
JP2019520416A5 (enExample)
JP2017523225A5 (enExample)
JP2017533930A5 (enExample)
JP2014111672A5 (enExample)
JP2018538273A5 (enExample)
JP2014122196A5 (enExample)
JP2020526538A5 (enExample)
US20200384007A1 (en) Lipid nanoparticles containing pharmaceutical and/or nutraceutical agents and methods thereof
RU2015146957A (ru) Производные доластатина 10 и ауристатинов
JP2019516739A5 (enExample)
BR112012019374A2 (pt) composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo
JP2013542261A5 (enExample)
JP2016515628A5 (enExample)
JP2016511753A5 (enExample)
JP2010132677A5 (enExample)
JP2015509075A5 (enExample)
JP2018521056A5 (enExample)
JP2017534654A5 (enExample)
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
JP2016514727A5 (enExample)
JP2014148552A5 (enExample)
JP2014530204A5 (enExample)